Filing Flows › AbCellera Biologics (ABCL) › Q2 2026 › vs Q1 2026
AbCellera Biologics (ABCL) Q2 2026 vs Q1 2026 (quarter over quarter)
AbCellera Biologics's revenue fell $4.3M (-51%) from $8.3M in Q1 2026 to $4.0M in Q2 2026. The biggest changes: Research fees −$4.2M (-52%); Licensing and royalty revenue −$42K (-22%).
AbCellera Biologics, Q2 2026: revenue $4.0M (-76% year over year), net loss $55.4M, operating cash flow $25.9M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 587.4% | -449.2% | +1036.7 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Research fees | $3.9M | $8.1M | −$4.2M | -52% |
| Licensing and royalty revenue | $149K | $191K | −$42K | -22% |
| Revenue | $4.0M | $8.3M | −$4.3M | -51% |
| Other income, net | $3.8M | $8.0M | −$4.2M | -52% |
| Income tax benefit | $3.5M | $6.4M | −$2.8M | -44% |
| Net loss | $55.4M | $43.2M | $12.3M | +28% |
| Costs & expenses | $66.8M | $65.8M | $993K | +2% |
| Operating costs | $66.8M | $65.8M | $993K | +2% |
| Research & development | $46.0M | $46.7M | −$675K | -1% |
| SG&A | $13.8M | $12.3M | $1.5M | +12% |
| Other operating costs | $7.0M | $6.8M | $152K | +2% |
| Operating cash sources | $81.3M | $9.6M | $71.7M | +744% |
| Depreciation & amortization | $7.0M | $6.8M | $152K | +2% |
| Share-based compensation | $12.3M | $12.0M | $273K | +2% |
| Working capital & other | $62.1M | −$9.2M | $71.3M | — |
| Net loss absorbed | $55.4M | $43.2M | $12.3M | +28% |
| Operating cash flow | $25.9M | −$33.5M | $59.4M | — |
| Free cash flow (OCF − capex) | $23.8M | −$37.4M | $61.1M | — |
| Capital expenditures | $2.1M | $3.8M | −$1.7M | -44% |
Questions
How much did AbCellera Biologics's revenue grow quarter over quarter in Q2 2026?
AbCellera Biologics's revenue fell $4.3M (-51%) from $8.3M in Q1 2026 to $4.0M in Q2 2026.
What drove AbCellera Biologics's revenue change in Q2 2026?
Research fees −$4.2M (-52%); Licensing and royalty revenue −$42K (-22%).